Xenetic Biosciences, Inc. XBIO · Stock Open Xenetic Biosciences, Inc. in new tab
Xenetic Biosciences, Inc. Analysis (XBIO)
Is Xenetic Biosciences, Inc. a good investment? Xenetic Biosciences, Inc. (XBIO) is currently trading at 2.02 USD.
Earnings Schedule: Xenetic Biosciences, Inc. is expected to release its next earnings report on Nov. 6, 2026. The market consensus estimate for Forward EPS is -0.66.
Investor FAQ
Does Xenetic Biosciences, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Xenetic Biosciences, Inc.?
Xenetic Biosciences, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 6, 2026. The company currently has a trailing EPS of -1.15.
Company Profile
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various research, development, license and supply agreements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
| Split Date | Split Ratio to 1 |
|---|---|
| June 6, 2016 | 0.03 |
| June 25, 2019 | 0.08 |
| May 15, 2023 | 1:10 |
Community Discussion